OKYO Pharma Limited (OKYO)
Automate Your Wheel Strategy on OKYO
With Tiblio's Option Bot, you can configure your own wheel strategy including OKYO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OKYO
- Rev/Share 0.0
- Book/Share -0.2152
- PB -10.4543
- Debt/Equity -0.0003
- CurrentRatio 0.2811
- ROIC 0.0006
- MktCap 84204668.0
- FreeCF/Share -0.0
- PFCF -348910.5148
- PE -28188.2016
- Debt/Assets 0.0006
- DivYield 0
- ROE 0.0004
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 2
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Published: June 11, 2025 by: Proactive Investors
Sentiment: Positive
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment in the underserved field of ocular pain. In a new note research report, Goldman Small Cap Research raised its price target on the stock to $8, up from $5, citing strong momentum, accelerated clinical progress, and growing interest from patients and clinicians alike in the company's lead drug candidate, urcosimod.
Read More
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research update on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target.
Read More
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
Published: May 19, 2025 by: Proactive Investors
Sentiment: Neutral
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston. Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he'll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain—a chronic eye condition that causes severe discomfort and currently has no approved therapies.
Read More
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens …
Read More
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
Published: May 01, 2025 by: Proactive Investors
Sentiment: Positive
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular condition with no FDA-approved therapies. The designation is intended to expedite the development and review of drugs targeting serious conditions with unmet medical needs.
Read More
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phase 2 trial being conducted at the Tufts Medical Center in Boston, Massachusetts, early, with 17 patients having completed the study.
Read More
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces plans to accelerate the clinical development of urcosimod to treat NCP through the analysis of its data following the early closure of its Phase 2 trial.
Read More
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
Published: March 10, 2025 by: Proactive Investors
Sentiment: Positive
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pain (NCP). The FDA's Fast Track designation is intended to accelerate the development and review of treatments for serious conditions with unmet medical needs, potentially expediting urcosimod's path to market if it is granted.
Read More
About OKYO Pharma Limited (OKYO)
- IPO Date 2022-05-17
- Website https://www.okyopharma.com
- Industry Biotechnology
- CEO Dr. Gary S. Jacob Ph.D.
- Employees 3